Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Chagas disease microbiome

PROVIDER: PRJEB22286 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2108230.fastq.gz	Fastqsanger.gz
	ERR2108240.fastq.gz	Fastqsanger.gz
	ERR2108250.fastq.gz	Fastqsanger.gz
	ERR2108260.fastq.gz	Fastqsanger.gz
	ERR2108270.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 847

Similar Datasets

mouse metagenome

Project description:Mouse GI Tract microbiome in Chagas Disease

| PRJNA553060 | ENA

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Search for SNPs associated with the pharmacogenomic profile of Benzidazole adverse reactions in Chagas Disease Homo sapiens patients.

2021-03-31 | GSE154421 | GEO

Comparison of Trypanosoma cruzi strains from patients with indeterminate and cardiac forms of Chagas disease

Project description:Gene expression profiles in T. cruzi strains isolated from individuals presenting the indeterminate and cardiac forms of Chagas disease. Genetic markers differentially expressed may be of potential use in diagnostic/prognostic tests and could assist the understanding of pathogenesis of Chagas disease Keywords: other

2005-10-08 | GSE1828 | GEO

Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model to Study Trypanosoma cruzi Infection

Project description:Human cardiomyocyte responses to Chagas disease

2019-06-24 | GSE129676 | GEO

Project description:Metagenome of Chagas disease vector

| PRJNA744378 | ENA

Project description:Transcriptomes of Chagas disease vectors

| PRJNA336218 | ENA

Immunologic changes are detectable in the peripheral blood transcriptome of clinically asymptomatic Chagas cardiomyopathy patients

Project description:Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a neglected parasitic disease that affects approximately 6 million individuals worldwide. Of those infected, 20-30% will go on to develop chronic Chagas cardiomyopathy (CCC), and ultimately many of these individuals will progress to advanced heart failure. The mechanism by which this progression occurs is poorly understood, as few studies have focused on early CCC. In this study, we sought to understand the physiologic changes associated with T. cruzi infection and the development of CCC. We analyzed gene expression in the peripheral blood of asymptomatic Chagas patients with early structural heart disease, Chagas patients without any signs or symptoms of disease, and Chagas-negative patients with and without early structural heart disease. Our analysis shows that early CCC was associated with a downregulation of various peripheral immune response genes, with gene expression changes suggestive of reduced antigen presentation and T cell activation. Notably, these genes and processes were distinct from those of early cardiomyopathy in Chagas-negative patients, suggesting that the processes mediating CCC may be unique from those mediating progression to other cardiomyopathies. This work highlights the importance of the immune response in early CCC, providing insight into the early pathogenesis of this disease. The changes we have identified may serve as biomarkers of progression and could inform strategies for the treatment of CCC in its early stages, before significant cardiac damage has occurred.

2024-10-04 | GSE244827 | GEO

High-throughput discovery of Chagas Disease antigens and their linear B-cell epitopes using high-density peptide arrays

Project description:Screening of antibody-binding specificities from pooled normal (healthy) and chronic Chagas Disease patients.

2015-06-24 | E-MTAB-3008 | biostudies-arrayexpress

Notch receptor expression in Trypanosoma cruzi infected Human Umbilical Vein Endothelial Cells treated with benznidazole or aspirin as revealed by microarray analysis

Project description:Chagas disease is a parasitic infection originally endemic to latinamerican countries but now spreaded worldwide that can be transmitted congenitally. Current specific therapy involves benznidazole, however, other therapies may modify gene expression that can change genetic expression profile, allowing cell programming to provide a more unfavorable environment for intracellular parasite development. Herein, microarray analysis was performed to Human Umbilical Vein Endothelial Cells (HUVEC), treated with benznidazole and the anti-inflammatory drugs aspirin or simvastatin, and infected with T. cruzi, the causative agent of Chagas disease.

2019-03-14 | GSE128270 | GEO

Project description:Brain transcriptome of a Chagas disease vector

| PRJNA853796 | ENA